TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17563739
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28 and interferon gamma (IFN-gamma) 0.025 mg/m² SQ every 2 days from day +7 to +28
Study: 15712603
Drug: Histamine releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine releasing test (HRT) for high suspicion level drugs
Study: 15712603
Drug: Interferon (INF)-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (INF)-gamma releasing test for high suspicion level drugs
Study: 15712603
Drug: CellScan method
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CellScan method for high suspicion level drugs
Study: 15712603
Drug: Histamine releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine releasing test (HRT) for low suspicion level drugs
Study: 15712603
Drug: Interferon (INF)-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (INF)-gamma releasing test for low suspicion level drugs
Study: 15712603
Drug: CellScan method
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CellScan method for low suspicion level drugs
Study: 10097871
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment options (including psychopharmacology)
Study: 2403654
Drug: Ceftriaxone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (100 mg/kg/day, intravenously once daily; n = 53)
Study: 2403654
Drug: Cefuroxime (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (240 mg/kg/day, intravenously in four equal doses; n = 53)
Study: 25442042
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with oxaliplatin (130 mg/m² on day 1) and capecitabine (1000 mg/m² twice daily for 14 days every 3 weeks), followed by chemoradiation therapy (50 Gy over 5 weeks with modified XELOX regimen), and then consolidation chemotherapy with XELOX regimen.
Study: 25442042
Drug: Neoadjuvant sandwich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant sandwich treatment using XELOX regimen as induction, concomitant, and consolidation chemotherapy.
Study: 19357442
Drug: Doxepin, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin, 10 mg, twice a day for 1 week
Study: 9839759
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl 1 mg
Study: 9839759
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl 3 mg
Study: 9839759
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl 5 mg
Study: 9839759
Drug: Donepezil HCl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil HCl (all doses)
Study: 7806692
Drug: Gepirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone (10 mg capsules, thrice daily, up to 120 mg daily)
Study: 2760597
Drug: Brief dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief dynamic therapy
Study: 31384338
Drug: Tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (5 mg IV)
Study: 23992935
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (IPE) 2 g/day
Study: 20336302
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of tamsulosin daily for 6 months
Study: 20336302
Drug: Tamsulosin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin after cessation of therapy
Study: 20336302
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after cessation of therapy
Study: 11917292
Drug: Pharmacologic agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic agents developed to ameliorate or prevent toxicities (specific agents not mentioned)
Study: 10070911
Drug: High-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose i.v. sodium ferric gluconate complex in sucrose (1.0 g)
Study: 10070911
Drug: Low-dose i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose i.v. sodium ferric gluconate complex in sucrose (0.5 g)
Study: 7588508
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g fat meal
Study: 7588508
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g fat meal
Study: 2188410
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g acetyl salicylic acid as effervescing tablets
Study: 31948926
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment in HARP-2
Study: 25122642
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of intravenous dexamethasone
Study: 23512440
Drug: 0.9 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/m2 beloranib
Study: 20666328
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + fentanyl 1.0 microg x kg(‐1) + atropine 0.5 mg (group FNT)
Study: 20666328
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + alfentanil 5.0 microg x kg(‐1) + atropine 0.5 mg (group ALFNT)
Study: 20666328
Drug: Pethidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 1.0 mg x kg(‐1) + atropine 0.5 mg (group Dolsin)
Study: 15925053
Drug: Mucoadhesive vaginal
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucoadhesive vaginal gel (MVG, Miphil) 2.5 g daily for the first week and then every 3 days for 5 weeks
Study: 15925053
Drug: Mucoadhesive vaginal
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucoadhesive vaginal gel (MVG, Miphil)
Study: 14700450
Drug: Controlled-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulations of bupropion, paroxetine, and venlafaxine
Study: 14700450
Drug: Immediate-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulations of bupropion, paroxetine, and venlafaxine
Study: 14700450
Drug: Fluoxetine (controlled-release)
Normalized name: fluoxetine Delayed Release Oral Capsule
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (controlled-release)
Study: 14700450
Drug: Fluoxetine (immediate-release)
Normalized name: fluoxetine Delayed Release Oral Capsule
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (immediate-release)
Study: 3523792
Drug: Pirenzepine (PZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PZ) 50 mg twice daily
Study: 3523792
Drug: Cimetidine (CM)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (CM) 400 mg twice daily
Study: 3523792
Drug: Pirenzepine (PZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PZ) 50 mg at night (maintenance)
Study: 3523792
Drug: Cimetidine (CM)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (CM) 400 mg at night (maintenance)
Study: 24664793
Drug: Claims-based measure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Claims-based measure of antipsychotic polypharmacy (90-day concurrent use of ≥2 antipsychotics, allowing for a 32-day gap)
Study: 18359433
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training (single session + daily practice tapes for one month)
Study: 10660814
Drug: Clonidine monotherapy
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine monotherapy
Study: 10660814
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) monotherapy
Study: 1565455
Drug: Twice-daily levobunolol
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily levobunolol (0.5%)
Study: 1565455
Drug: Once-daily levobunolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily levobunolol (0.5%)
Study: 23697261
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (15 days treatment)
Study: 15042429
Drug: AC+CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC+CC genotype of AT1
Study: 11305827
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lidocaine plus 10 microg sufentanil
Study: 11305827
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lidocaine plus 10 microg sufentanil plus epinephrine 50 microg
Study: 9029223
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (IV) 1.3 g/kg
Study: 9029223
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (PO) 1.3 g/kg
Study: 7705854
Drug: Trimethoprim 320
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim 320 mg/sulphamethoxazole 1600 mg by mouth for 2 days (TMPSMX)
Study: 7705854
Drug: Amoxicillin 3
Normalized name: amoxicillin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once (APC)
Study: 7705854
Drug: Amoxicillin 3
Normalized name: amoxicillin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 3 gm, probenicid 1 gm, and clavulanate 125 mg by mouth once with doxycycline 100 mg BID for 7 days (APC-D)
Study: 7705854
Drug: Gentamicin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 240 mg IM once (GENT)
Study: 7705854
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg by mouth once (CIPRO)
Study: 3129938
Drug: Low-dose alcohol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alcohol consumption (one beverage per day)
Study: 29417831
Drug: Aquatic exercise
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic exercise (n=31), 8-week treatment protocol, 16 individual sessions, twice a week
Study: 25636328
Drug: Genotyping for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotyping for CYP2D6 with dosing advice communicated to the treating physician
Study: 9673299
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg of OspA vaccine
Study: 23918037
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every other week (Q2W), reduced to 200 mg Q2W after ≥6 months + Methotrexate (MTX)
Study: 22454006
Drug: Flexible extended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible extended regimen with MIB (minimum 24, maximum 120 days of continuous tablet intake)
Study: 22454006
Drug: Conventional 28-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 28-day regimen (24 active and four placebo tablets for five cycles)
Study: 12866946
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg test formulation
Study: 12866946
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg reference formulation
Study: 1828570
Drug: Calcium entry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium entry blockers (CEB)
Study: 30585459
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia group
Study: 24439636
Drug: Lavender aromatherapy
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender aromatherapy (10% concentration inhaled for 5 minutes during 3 hemodialysis sessions)
Study: 22936194
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg/h plus Ketamine 5 µg/kg/min and Remifentanil 0.1 µg/kg/min (GK)
Study: 22936194
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg/h plus Remifentanil 0.25 µg/kg/min (GR)
Study: 19834700
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 300 mgI/mL
Study: 19834700
Drug: 80 mL
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mL of 370 mgI/mL
Study: 19834700
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL of 370 mgI/mL followed by a 30‐mL saline flush
Study: 17393343
Drug: Int3 (intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Int3 (intensified antidiabetic therapy for 3 weeks)
Study: 17393343
Drug: Int52 (intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Int52 (intensified antidiabetic therapy for 52 weeks)
Study: 17393343
Drug: Con3 (unchanged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Con3 (unchanged therapy for 3 weeks)
Study: 17393343
Drug: Con52 (unchanged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Con52 (unchanged therapy for 52 weeks)
Study: 11872998
Drug: Concentration-controlled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-controlled therapy (zidovudine, lamivudine, and indinavir)
Study: 11872998
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (zidovudine, lamivudine, and indinavir)
Study: 11872998
Drug: Both concentration-controlled
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both concentration-controlled and conventional therapy
Study: 9607949
Drug: Nonliposomal (oil/water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonliposomal (oil/water cream) delivery system
Study: 30734476
Drug: Ultrasound-guided cervical
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided cervical nerve root block (CRB) with mixed drug liquid
Study: 29045212
Drug: 5-mg tofacitinib
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg tofacitinib
Study: 29045212
Drug: 10-mg tofacitinib
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg tofacitinib
Study: 29045212
Drug: placebo (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (switched to 5-mg tofacitinib at 3 months)
Study: 29045212
Drug: placebo (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (switched to 10-mg tofacitinib at 3 months)
Study: 16952814
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of morphine in 10 mL of saline
Study: 10195529
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of saline
Study: 9322512
Drug: Fructose-glucose (FruGlu)
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose-glucose (FruGlu) solution
Study: 9322512
Drug: Fructose-glucose-acarbose (FruGluA)
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose-glucose-acarbose (FruGluA) solution
Study: 9322512
Drug: Lactulose absorption
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose absorption from glucose or sucrose solutions
Study: 9322512
Drug: Fructose-mannitol (FruMann)
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose-mannitol (FruMann) solution
Study: 9322512
Drug: Sucrose, FruGlu,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose, FruGlu, and glucose solutions
Study: 8373602
Drug: Midazolam (MZ)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (MZ) 0.02 mg/kg i.v., repeated every 2 to 3 minutes; maintenance MZ 0.005 mg/kg i.v. as necessary
Study: 8373602
Drug: Propofol bolus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol bolus (PB) 0.75 to 1.0 mg/kg i.v.; maintenance 0.25 mg/kg i.v. as necessary
Study: 8373602
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (PI) 2 to 4 mg/kg/hr or 33 to 66 micrograms/kg/min to maintain SL3
Study: 3539031
Drug: Nebulised beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised beclomethasone dipropionate suspension
Study: 30171484
Drug: Mannitol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (12 g)
Study: 25234606
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial direct current stimulation (tDCS) administered in 15 30-minute treatments over three weeks
Study: 25234606
Drug: Sham condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham condition administered in 15 30-minute treatments over three weeks
Study: 18269775
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 twice daily for 14 days followed by 7 days of rest
Study: 18269775
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 twice daily
Study: 10595949
Drug: (99m)Tc‐sestamibi injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc‐sestamibi injection (20 to 30 mCi) before primary angioplasty
Study: 1878612
Drug: Videotaped behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped behavioral treatment program
Study: 6682026
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion at a rate of 20 micrograms kg‐1 hr‐1
Study: 3887976
Drug: Oral tiaramide
Normalized name: stearamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tiaramide 200 mg four times daily
Study: 3887976
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol 4 mg four times daily
Study: 3887976
Drug: Oral tiaramide
Normalized name: stearamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tiaramide
Study: 25355194
Drug: Paracetamol/acetaminophen 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/acetaminophen 500 mg thrice daily
Study: 25355194
Drug: Placebo (empty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (empty capsules)
Study: 20158920
Drug: Aerobic-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic-based exercise training (6 months, thrice-weekly)
Study: 2500169
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg twice daily for 16 weeks
Study: 2500169
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 mg twice daily for 16 weeks
Study: 815189
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg, three times a day for 2 days)
Study: 10206132
Drug: Early dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early dexamethasone treatment (from day 7)
Study: 10206132
Drug: Late dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Late dexamethasone treatment (from day 14)
Study: 7774174
Drug: Fluoride therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride therapy only (control group)
Study: 2078794
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (radiation in combination with 5-FU)
Study: 22331521
Drug: Hibiscus sabdariffa
Normalized name: HIBISCUS SABDARIFFA CALYX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabdariffa L. aqueous extract (HSE)
Study: 20089827
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg/d for 1 week
Study: 16900082
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (1-18 microg/daily)
Study: 15338103
Drug: Methylphenidate (30
Normalized name: methylphenidate (30/70 release) 10 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (30 mg single dose)
Study: 10850384
Drug: Consensus Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus Interferon (CIFN), 9 microg, subcutaneous injection, three times weekly for 24 weeks
Study: 10850384
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (IFN alfa‐2b), 3 MU, subcutaneous injection, three times weekly for 24 weeks
Study: 10850384
Drug: Serotype or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype or genotype 2 or 3 (independently of treatment)
Study: 8565197
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate ophthalmic solution (0.1%)
Study: 7020900
Drug: alpha-methyldopa (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-methyldopa (750 mg/d orally)
Study: 7020900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpha-methyldopa and chlorothiazide